CLOs on the Move

Steininger Behavioral Care Services

www.sbcs.us

 
Steininger Behavioral Care Services is a Cherry Hill, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sbcs.us

  • Cherry Hill, NJ USA 08034
  • Phone: 856.428.1300

Executives

Name Title Contact Details

Similar Companies

X-elitec

X-elitec is a Fuquay Varina, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brooks Rehabilitation

Our foundation supports many programs throughout the Brooks System of Care, including clinical research, adaptive sports and wellness, school re-entry, and free care for those who need it most. Our Volunteer Services department provides an opportunity for personal growth, education, and service to others. Our goal is to meet the needs of our volunteers while carrying out our vision of providing world-class service to our patients. Volunteer assignments are made according to interest, availability, and the skills needed to fulfill task requirements.

Pacific Hospitalist Associates

Pacific Hospitalist Associates is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Benchmarks Inc

Health Benchmarks Inc is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.